Search

Displaying results 451 - 460 of 9613 in total
  1. Drug

    Riociguat

    go.drugbank.com/drugs/DB08931
    ApprovedInvestigational

    Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for

    Products: Adempas 1mg film-coated tablet, Adempas 2.5mg film-coated tablet
  2. Drug

    Phenytoin

    go.drugbank.com/drugs/DB00252
    ApprovedInvestigationalVet approved

    Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants. … [A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications

    Mixtures: Dilantin W Phenobarbital 15mg, Dilantin W Phenobarbital 30mg CapProducts: Dilantin Inj 50mg/ml, DILANTIN CAPSULE 30MG
  3. Drug

    Dronabinol

    go.drugbank.com/drugs/DB00470
    ApprovedIllicitInvestigational

    THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased … Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana).

    Products: Marinol Cap 10mg
  4. Drug

    Trabectedin

    go.drugbank.com/drugs/DB05109
    ApprovedInvestigational

    Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. … Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery.

    Products: YONDELIS 1MG FOR INJECTION, YONDELIS Powder for Injection 1mg/vial
  5. Drug

    Ustekinumab

    go.drugbank.com/drugs/DB05679
    ApprovedInvestigational

    [A187349] It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. … In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults.

    Products: Stelara Solution for Injection 45mg/0.5 ml, Solution for Injection 90mg/1ml
  6. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    [L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018. … [A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe.

    Products: OLUMIANT FILM-COATED TABLET 2MG, OLUMIANT FILM-COATED TABLET 4MG
  7. Drug

    Celecoxib

    go.drugbank.com/drugs/DB00482
    ApprovedInvestigational

    [A181532] It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. … [A181544] It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon.

    Products: Rabirox Capsule 400mg, CELEBREX CAPSULE 400MG
  8. Drug

    Parecoxib

    go.drugbank.com/drugs/DB08439
    ApprovedInvestigational

    As it is injectable, it can be used perioperatively when patients are unable to take oral medications. … It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx).

    Products: PARECOXB parecoxib (as sodium) 40mg powder for solution for injection, DYNASTAT INJECTION 40MG
  9. Drug

    Lorlatinib

    go.drugbank.com/drugs/DB12130
    ApprovedInvestigational

    It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to … include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.

    Products: LORVIQUA FILM-COATED TABLET 25MG, LORVIQUA FILM-COATED TABLET 100MG
  10. Drug

    Ketotifen

    go.drugbank.com/drugs/DB00920
    ApprovedInvestigational

    It has a similar structure to some other first-generation antihistamines such as [cyproheptadine] and [azatadine]. … [A231204] Ketotifen was first developed in Switzerland in 1970 by Sandoz Pharmaceuticals and was initially marketed for the treatment of anaphylaxis.

    Products: KETOTIFENE EG, PMS-ketotifen